Cost concerns among GLP-1 users extend beyond individual financial strain to perceptions of broader health care system sustainability. More than 70% of respondents supported minimum coverage ...

Find insight on WELL Health Technologies, Novo Nordisk and more in the latest Market Talks covering Health Care.

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

These patients, who may have high-deductible health plans or co-insurance, will be able to purchase both the pill and injection forms of obesity treatment Wegovy, the Ozempic diabetes shot, and oral ...

Novo Nordisk announced up to 50% price cuts for Ozempic and Wegovy diabetes and weight-loss drugs starting January 2027, ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

Chronic cough has not traditionally been listed as a common adverse effect of GLP-1s. According to Jeff Stanley, MD, ...

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years. Despite its clinical success, its precise molecular and cellular ...

Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and ...

Fresh off a failed trial that sent its shares plummeting, Novo Nordisk said that one of its experimental obesity drugs helped patients lose nearly 20% of their weight after 24 weeks in a midstage tria ...